AMO monovision procedure approved for presbyopia

AMO has received FDA approval for the Advanced CustomVue Monovision procedure, the first wavefront-guided procedure for the correction of myopic prebyopes, with or without astigmatism.

The Monovision treatment is designed to improve both near and distance vision by first mapping and then custom correcting nearsightedness in the dominant eye and partially correcting nearsightedness in the second eye. The procedure is individualized for the unique correction requirements of presbyopic patients with low to moderate myopia with or without astigmatism, resulting in a reduced dependency on reading glasses and contact lenses.

The FDA approval is based on clinical data from a multicentre clinical trial, which involved 160 patients for up to two years. In the trial, 100% of patients achieved 20/40 or better vision at both distance and near.